RATIO-LISINOPRIL Z TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

LISINOPRIL

Tilgjengelig fra:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC-kode:

C09AA03

INN (International Name):

LISINOPRIL

Dosering :

10MG

Legemiddelform:

TABLET

Sammensetning:

LISINOPRIL 10MG

Administreringsrute:

ORAL

Enheter i pakken:

100/500

Resept typen:

Prescription

Terapeutisk område:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produkt oppsummering:

Active ingredient group (AIG) number: 0121550001; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2014-09-19

Preparatomtale

_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 39 _
PRODUCT MONOGRAPH
RATIO-LISINOPRIL Z
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
DATE OF PREPARATION: SEPTEMBER 20, 2007
CONTROL NUMBER: 110419
_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
……………………………………………………..4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................... 19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND
STABILITY.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL
INFORMATION.........................................................................
23
CLINICAL
TRIALS.........................................................................................................
24
DETAILED
PHARMACOLOGY...............................................................